Mirum Pharmaceuticals (MIRM) Retained Earnings (2018 - 2026)

Mirum Pharmaceuticals' Retained Earnings history runs 9 years deep, the most recent figure standing at -$28000.0 for Q1 2026.

• In Q1 2026, Retained Earnings rose 89.15% year-over-year to -$28000.0; the TTM figure through Mar 2026 stood at -$28000.0 (up 89.15% YoY), while the FY2025 annual figure was -$667.5 million, down 3.63% from the prior year.
• Retained Earnings was -$28000.0 for Q1 2026 at Mirum Pharmaceuticals, up from -$667.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $920000.0 in Q3 2024 to a low of -$667.5 million in Q4 2025.
• Historically, Retained Earnings has averaged -$244.5 million across 5 years, with a median of -$258000.0 in 2025.
• Biggest YoY gain for Retained Earnings was 203.82% in 2023; the steepest drop was 256231.34% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$217000.0 in 2022, then slumped by 256231.34% to -$556.2 million in 2023, then dropped by 15.81% to -$644.2 million in 2024, then slipped by 3.63% to -$667.5 million in 2025, then surged by 100.0% to -$28000.0 in 2026.
• The last three Retained Earnings figures came in at -$28000.0 (Q1 2026), -$667.5 million (Q4 2025), and $37000.0 (Q3 2025), per Business Quant data.